Farxiga/Forxiga is not currently approved for weight loss as a standalone indication in non-diabetics, but the evidence is accumulating: Currently, if weight loss is the primary goal in a non-diabetic patient, GLP-1 agonists (semaglutide/Ozempic, tirzepatide/Mounjaro) produce substantially greater weight loss (1015% vs 24%)
The payload (often an auristatin, maytansine, or camptothecin derivative) is covered by synthesis and method-of-use patents
Because of this multi-pathway approach, emerging research suggests retatrutide may lead to greater overall weight loss, while semaglutide remains one of the most widely used and trusted medications for appetite control and metabolic support
Available from: Stylianopoulos T, Munn LL, Jain RK
It offers numerous benefits that can significantly improve your quality of life: Effective weight management Blood sugar regulation Reduced cardiovascular risk Improved metabolic health Enhanced satiety and appetite control Potential for better overall health outcomes Our team at Dawn of Life Aesthetics & Wellness is committed to helping you understand and harness the power of GLP-1 for your health goals
